

Be the Change... An Advocacy Boot Camp (P18)
Sponsored by the AAHPM Public Policy Committee

Sue Ramthun Hart Health Strategies, Washington, DC. Phillip E. Rodgers, MD FAAHPM, University of Michigan, Ann Arbor, MI. Paul E. Tatum III, MD MSPH CMD AGSF FAAHPM, University of Missouri, Columbia, MO. Ruth M. Thomson, DO HMDC FACOI FAAHPM, Hospice of Dayton, Inc., Dayton, OH. Gregg K. VandeKieft, MD MA FAAHPM, Providence St. Peter Hospital, Olympia, WA.

Objectives

- Understand how healthcare professionals can influence the legislative and regulatory processes and why it is important to do so.
- Identify current health policy developments with implications for hospice and palliative care.
- Use effective grassroots communication techniques and other strategies for successful advocacy.

Are you frustrated by increasing regulatory burdens on your practice, concerned about efforts to restrict opioid prescribing, or anxious about whether emerging healthcare payment and delivery models will work for hospice and palliative care? Lawmakers and regulators rely on input from constituents and stakeholders when crafting health care policy; is yours the voice they are hearing? If not, come participate in this interactive workshop and learn how to become an effective advocate for your patients, your practice, and your profession. It's easier than you think—and you don't have to travel to Washington, DC, to make a difference!

In this advocacy “boot camp” sponsored by AAHPM's Public Policy Committee, you'll hear from government relations experts and colleagues with a wealth of advocacy experience in the legislative and regulatory arenas at both the state and federal levels. Come learn about effective grassroots communication and how to shape your messaging for maximum impact. Whether planning local meetings with elected officials and their staff, attending a town hall, engaging on social media, or responding to a call for public comments on proposed regulations, you'll benefit from the tips, tools, and resources this workshop will highlight. The session will also include a brief overview of the public policy process, priority issues for the field of hospice and palliative care, and federal legislation that would benefit patients with serious illness and the providers who care for them.

First-timers and experienced advocates looking for a refresher will appreciate the opportunity to ask questions of our experts and share stories from the front lines. You'll be able to apply the lessons learned, whether advocating for sound public policy or working

to advance palliative care within your institution. In today's evolving healthcare marketplace, hospice and palliative care professionals simply can't afford *not* to make advocacy part of their job description!

ER/LA Opioids: Achieving Safe Use While Improving Patient Care (P19)

Objectives

- Summarize why risk evaluation and mitigation strategies (REMS) are necessary for opioid drugs.
- Effectively assess benefits and risks of prescribing extended release/long-acting (ER/LA) opioids.
- Define the concepts and federal and state regulations regarding effectively initiating, modifying dosing, and discontinuing ER/LA opioids.
- Apply strategies to effectively manage risk of side effects, abuse, and diversion.
- Counsel patients and families about general characteristics, risks, and safe management of ER/LA opioids.
- Apply general information and specific characteristics of ER/LA opioids in practice.

The US Food and Drug Administration (FDA) has determined that a risk evaluation and mitigation strategy (REMS) is required for extended-release (ER) and long-acting (LA) opioid medications to ensure that their benefits outweigh their risks. AAHPM has been a strong advocate of availability of these medications for use in palliative and hospice care settings while acknowledging the significant increase of unintentional deaths, emergency department visits, and admissions to substance abuse treatment due to abuse of pain relievers. Prescriber education and patient education are vital components of these REMS. This workshop will cover all six content areas defined in the FDA's Blueprint for Prescriber Continuing Education Program, refined specifically for hospice and palliative care prescribers. While prescriber education is currently voluntary, mandates are anticipated through federal legislation in the near future. Anticipate an engaging, case-based session that informs your practice going forward.

Prognosticating the Survival of the Hospice Industry (P20)

Judy Bartel, ACHPN[®] CHPCA[®] FPCN[®], Chief Clinical Officer Hospice of the Western Reserve. William Finn, MBA, Hospice of the Western Reserve, Cleveland, OH. Clement J. Hearey, MBA, Hospice of the Western Reserve, Cleveland, OH.

Objectives

- Discuss the Affordable Care Act's impact on hospice sustainability.
- Discuss the future roles of quality, value propositions, and varied service models.